Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cleave Therapeutics

Request full access

Developing Novel Protein Degradation Inhibitors for the Treatment of Cancer

San Francisco, United StatesFounded 2010Biotech & Life Sciences

About Cleave Therapeutics

Cleave Biosciences, which later became Cleave Therapeutics, was a clinical-stage biopharmaceutical company established in 2011 to develop novel therapies for cancer and neurodegenerative diseases. The company was founded by a team of scientists including Raymond Deshaies, Ph.D., Seth Cohen, Ph.D., and Francesco Parlati, Ph.D., with initial leadership from CEO Laura Shawver, Ph.D. Dr. Deshaies, a world-renowned expert in protein degradation pathways, had previously co-founded Proteolix, the company behind the successful oncology drug carfilzomib. Dr. Shawver, a seasoned biotech executive and cancer survivor herself, brought over two decades of experience in developing small molecule drugs for cancer, which shaped the company's patient-centric approach.

The company's core focus was on inhibiting the valosin-containing protein (VCP)/p97, a critical enzyme that regulates protein homeostasis—a process that cancer cells become overly dependent on for survival. By targeting VCP/p97, Cleave aimed to disrupt multiple cellular stress pathways, pushing cancer cells toward apoptosis. The business model centered on the discovery and clinical development of small-molecule inhibitors targeting this pathway, with the goal of creating first-in-class drugs for patients with difficult-to-treat cancers. Revenue generation was planned through licensing agreements and the eventual commercialization of its drug candidates. A significant milestone was a 2021 licensing agreement with CASI Pharmaceuticals to develop and commercialize its lead candidate in Greater China, which involved a $5.5 million upfront payment and potential for $74 million in milestones plus royalties.

Cleave's lead product candidate was CB-5339, a second-generation, oral, selective inhibitor of VCP/p97. This compound was designed to overcome the limitations of earlier inhibitors, offering better target selectivity and exposure. The company advanced CB-5339 into a Phase 1 clinical trial for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial, which began in 2020, showed the drug was well-tolerated and demonstrated signs of clinical activity. In a major strategic development in July 2023, Cleave's assets were acquired by two separate entities: CASI Pharmaceuticals acquired the global rights to the clinical asset CB-5339, while Eikon Therapeutics acquired the company's preclinical assets and chemical library to explore other novel targets.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
60.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Alternative Protein, Macro-Nutrients, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B, B2C

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Aug 2019 $12M $48M Celgene · U.S. Venture Partners · Bristol-Myers Squibb · OrbiMed —
SERIES BOther financing Aug 2016 $37M $148M 5AM Ventures · Clarus Ventures · Osage University Partners · NEA —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Cleave Therapeutics website traffic

Latest recorded traffic for Cleave Therapeutics is 2.6K monthly website visits, up 62.5% over the last three months. Cleave Therapeutics's team grew 0% over the past year.

Latest monthly visits2.6K 3-month web change+62.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cleave Therapeutics in the San Francisco ecosystem

Live from Dealroom

The Cleave Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • 5AM Ventures
  • NEA
  • Clarus Ventures
  • Osage University Partners
  • Arcus Ventures
  • Celgene
  • OrbiMed
  • Astellas Venture
  • Nextech Invest

Series B and later2 investors entered at this stage

Other known investors1 additional known investor

  • Rush University
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cleave Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cleave Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.